

A transient CRISPR/Cas9 expression system for genome editing in *Trypanosoma brucei*

Sebastian Shaw

Universität Bern

Sebastian Knüsel

Universität Bern

Sarah Hoenner

Universität Bern

Isabel Roditi (✉ isabel.roditi@izb.unibe.ch)

Universität Bern <https://orcid.org/0000-0003-2812-6513>

Research note

Keywords: CRISPR/Cas9, transient transfection, trypanosome

Posted Date: May 20th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-21224/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Research Notes on June 3rd, 2020.

See the published version at <https://doi.org/10.1186/s13104-020-05089-z>.

Abstract

Objective Generation of knockouts and in situ tagging of genes in *Trypanosoma brucei* has been greatly facilitated by using CRISPR/Cas9 as a genome editing tool. To date, this has entailed using a limited number of cell lines that are stably transformed to express Cas9 and T7 RNA polymerase (T7RNAP). It would be desirable, however, to be able to use CRISPR/Cas9 for any trypanosome cell line.

Results We describe a sequential transfection expression system that enables transient expression of the two proteins, followed by delivery of PCR products for gRNAs and repair templates. This procedure can be used for genome editing without the need for stable integration of the Cas9 and T7RNAP genes.

Introduction

The establishment of genome editing by CRISPR/Cas9 in trypanosomatids has greatly increased the ease with which knockouts can be generated, as two copies of a non-essential gene can often be deleted in a single round of transfection. The system most widely used for *Trypanosoma brucei* entails creating cell lines which express (either constitutively or inducibly) both Cas9 to generate a DNA double-strand break and T7RNAP for the transcription of guide RNAs from a DNA template [1–4]. The original pTB011 plasmid generated for *T. brucei* [4] encodes Cas9 flanked by tubulin sequences, enabling the construct to be integrated into the corresponding multicopy array. We modified this plasmid by replacing the puromycin acetyltransferase gene with that of T7RNAP, giving rise to pTB011_Cas9_T7RNAP_blast (Figure 1A). This plasmid allows generation of CRISPR/Cas9-competent cell lines, constitutively expressing T7RNAP and Cas9 from the tubulin locus, in a single round of transfection [5]. Further modification of this plasmid, and optimisation of the transfection protocol for transient expression of the proteins and guide RNAs, are described below.

Results

In order to expand the range of cell lines that can be genetically modified by CRISPR/Cas9, without the need for stable transformation, we developed a protocol for transient expression of all three components (Cas9, T7RNAP and guide RNAs) in *T. brucei*. The plasmid All-in-one-Cas9 (pAi1C9; Figure 1B) was constructed by replacing the α -tubulin sequence upstream of T7RNAP with 366 bp of the EP procyclin promoter and 5' UTR [6].

To test the functionality of the plasmid, we used the LeishGEdit software [4] to design a guide RNA that allows tagging of the C-terminus of phosphodiesterase B1 (PDEB1) with mNeonGreen (mNG). The repair template, in the form of a purified PCR product, including homology arms of 30 bp on each side, was amplified from pPOTv7 [7]. As a positive control we transfected a derivative of *T. brucei* Lister 427 procyclic forms that already expresses Cas9 and T7RNAP constitutively (Lister 427/Cas9) [5]. This gave rise to cells with a fluorescent flagellum as expected (tryptag.org) (Figure 2A).

For genome editing by transient expression of Cas9 and T7RNAP, we tested two different transfection schemes. Initially, all components were transfected simultaneously: the circular plasmid pAi1C9 encoding Cas9 and T7RNAP, the DNA template for *in vivo* transcription of a guide RNA, and the DNA repair template harbouring mNG for C-terminal tagging and a hygromycin resistance gene. This procedure gave few hygromycin-resistant clones, only 10 clones in total, from 4 separate transfections. These clones either did not express mNG (4 clones), or expressed it as a cytoplasmic protein (2 clones) or expressed it correctly localised to the flagellum (4 clones). Examples are shown in Figure 2B. We hypothesise that, due to insufficient expression of Cas9 and T7RNAP, the amounts of site-specific guide RNAs and double-strand breaks at the correct locus were too low to drive efficient integration by homology-directed repair.

We therefore tested sequential transfections in which we first used pAi1C9 to enable expression of Cas9 and T7RNAP. A second transfection 20 h later provided the templates for the gRNA and the mNG repair construct. The same electroporation conditions were used for the plasmid and the templates (see Methods and Figure 3). This procedure yielded 20 clones. There were 16 clones in which mNG was correctly localised to the flagellum, one in which it was cytoplasmic, 2 clones with mixed populations of mNG localised either to the flagellum or the cytoplasm, and one that was negative (see Figure 2B for representative examples). One clone with flagellar mNeonGreen had a fluorescence intensity twice that of the others (clone B1) and might have been tagged on both alleles.

We have also used this procedure of sequential transfections to simultaneously knock out both copies of trypanin or GPI-anchor transamidase subunit 8 (GPI8), which are non-essential genes in cultured procyclic form *T. brucei* [8, 9]. Genotyping data is provided in Additional File 1.

Methods

Transfection of pAi1C9:

4×10^7 *T. b. brucei* 427 procyclic forms were transfected with 10 μ g pAi1C9 dissolved in 100 μ l TbBSF transfection buffer [10], using an Amaxa Nucleofector IIb (Lonza), program X-014 [11]. Cells were transferred to 13 ml SDM79 medium [12] supplemented with 10 % FBS and incubated at 27 °C and 2.5 % CO₂ for 20 hours.

Transfection of pooled PCR products for repair constructs and sgRNA templates:

The entire culture from the first transfection was centrifuged at 1700 g for 5 min, the supernatant discarded and the cells resuspended in 100 μ l TbBSF transfection buffer containing the pooled PCR products (see protocol for PCRs below). For tagging one sgRNA template (targeted to the 3' end of the ORF) and one repair template (hygromycin resistance) were provided; to generate the knockouts, we provided two sgRNA templates (targeted to the 5' and 3' ends of the ORF) and two repair templates (hygromycin and neomycin resistance genes).

Transfection was performed as described above and the cells were transferred to 10 ml SDM79 supplemented with 10 % FBS. The cells were diluted 1:5, 1:50 and 1:500 in conditioned medium (fresh medium + 20 % supernatant of a log-phase culture) and distributed into 24-well plates (1 ml in each well). Transformants were selected using 25 μ g ml⁻¹ Hygromycin B and/or 15 μ g ml⁻¹ Geneticin; stable clones were obtained two weeks post selection.

Polymerase chain reactions (PCR):

Reactions were performed with reagents from New England Biolabs: Phusion High-Fidelity DNA polymerase (M0530S), 5 x Phusion HF buffer (B0519S) and dNTP mix (N0447S). Cycling conditions are identical to those previously published [4, 13].

-1st PCR: template for sgRNAs; two 20 μ l reactions per target

1 μ l	G00 primer (0.5 μ M)
4 μ l	5 x Phusion HF buffer
0.5 μ l	dNTP mix (250 μ M)
1 μ l	sgRNA primer (0.5 μ M)
0.2 μ l	Phusion High-Fidelity DNA polymerase (0.4U)
13.3 μ l	H ₂ O

-Program:	1)	30", 98 °C
	2)	10", 98 °C
	3)	30", 60 °C

- 4) 15", 72 °C
- 5) go to step 2, 35 cycles in total
- 6) 10', 72 °C
- 7) hold at 10 °C

-2nd PCR: template for resistance gene; two 40 µl reactions per resistance gene

2 µl	60 ng pPOTv7 mNG (hygro or G418) plasmid
8 µl	5 x Phusion HF buffer
1 µl	dNTP mix (250 µM)
2 µl	Upstream forward primer (0.5 µM)
2 µl	Downstream reverse KO/TAG primer (0.5 µM)
0.4 µl	Phusion High-Fidelity DNA polymerase (0.4U)
24.6 µl	H ₂ O

- Program:
- 1) 5', 94 °C
 - 2) 30", 94 °C
 - 3) 30", 65 °C
 - 4) 2'30", 72 °C
 - 5) go to step 2, 40 cycles in total
 - 6) 10', 72 °C
 - 7) hold at 10 °C

DNA purification after PCR:

PCR reactions were pooled and extracted with 1 volume water-saturated phenol (pH 8), followed by extraction with 1 volume chloroform. DNA was precipitated from the aqueous phase by addition of 0.1 volume 3 M sodium acetate, pH 5.2, and 3 volumes ice-cold ethanol. The DNA was pelleted by centrifugation, washed twice with 1 ml 80 % ethanol, air-dried at room temperature, dissolved in 40 µl Milli-Q-water and stored at -20°C until transfection.

Primers:

G00: aaaagcaccgactcggtgccacttttcaagttgataacggactagccttatttaacttgctatttctagctctaaaac

PDEB1 3' sgRNA primer:

gaaattaatacgactcactataggTGAAGAAGTCAGTTGACCGGgttttagagctagaaatagc

Trypanin 5' sgRNA primer:

gaaattaatacgactcactataggCAAAAACGAGAAGAGCCTACgttttagagctagaaatagc

Trypanin 3' sgRNA primer:

gaaattaatacgactcactataggAGGTGTTGTGGTTCACACGTgttttagagctagaaatagc

GPI8 5' sgRNA primer:

gaaattaatacgactcactataggCGGTTGCAAAAACGAATGCgttttagagctagaaatagc

GPI8 3' sgRNA primer:

gaaattaatacgactcactataggGGTATGTCCCATCAGTTGGAgtttagagctagaaatagc

Trypanin upstream forward primer:

TACTTTTCAGACTGCATCGTGGCGTACCCCgtataatgcagacctgctgc

Trypanin downstream reverse KO primer:

CTGCAACAAAGCCGTA ACTTGGAAACAACC Accggaaccactaccagaacc

PDEB1 downstream forward primer:

ACGAGTTCTGGCAACAACAGCAGTACTCGTggttctggtagtggttccgg

PDEB1 downstream reverse TAG:

ATCACCATTGACAAGAACGTACATCTACCAccaatttgagagacctgtgc

GPI8 upstream forward primer:

TTGGATCAGGCGCTTGCATATTTATTTCCAgtataatgcagacctgctgc

GPI8 downstream reverse KO primer:

AGTTTCAGGAAGGAAGTTCGTTTTTCTCCTccggaaccactaccagaacc

Limitations

Transient transfection with pAi1C9 gives rise to fewer clones than cell lines that are stably transformed with the T7RNAP and Cas9 genes. It has the advantage, however, that it can be applied to any *T. brucei* cell line. Moreover, in contrast to stable integration of the CRISPR/Cas9 machinery, transient transfection does not require additional selectable markers and it has the added advantage that it circumvents possible Cas9 toxicity. In addition to using Cas9 for deletion, mutation, tagging or integration of ectopic copies, this procedure could also be adapted for nuclease inactive Cas9 variants for targeting RNAs or epigenetic modifications [14, 15].

Abbreviations

mNG, mNeonGreen; PDEB1, phosphodiesterase B1; T7RNAP, T7 RNA polymerase;

Declarations

Acknowledgements

We thank Eva Gluenz (University of Glasgow) for providing the progenitor plasmid pTB011 and David Schädeli and Peter Bütikofer for initiating us into CRISPR/Cas9 technology.

Funding

Swiss National Science Foundation (grant nos. 31003A_166427 and 310030_184669) and the Canton of Bern.

Authors' contributions

Designed study: SS and IR; performed experiments: SS, SH and SK; analysed data: SS, SK and IR; wrote the paper: SS, SK and IR.

Availability of data and material

Plasmids are available on request from Isabel Roditi (Isabel.roditi@izb.unibe.ch). The nucleotide sequences of pTB011_Cas9_T7RNAP_blast and pAi1C9 are provided on this website: https://www.izb.unibe.ch/research/prof_dr_isabel_roditi/index_eng.html

Competing interests

We, the authors, declare no conflict of interests.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

References

1. Vasquez J-J, Wedel C, Cosentino RO, Siegel TN. Exploiting CRISPR-Cas9 technology to investigate individual histone modifications. *Nucleic Acids Res.* 2018;46:e106–e106. doi:10.1093/nar/gky517.
2. Soares Medeiros LC, South L, Peng D, Bustamante JM, Wang W, Bunkofske M, et al. Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins. *MBio.* 2017;8:e01788-17. doi:10.1128/mBio.01788-17.
3. Rico E, Jeacock L, Kovářová J, Horn D. Inducible high-efficiency CRISPR-Cas9-targeted gene editing and precision base editing in African trypanosomes. *Sci Rep.* 2018;8:7960. doi:10.1038/s41598-018-

4. Beneke T, Madden R, Makin L, Valli J, Sunter J, Gluenz E. A CRISPR Cas9 high-throughput genome editing toolkit for kinetoplastids. *R Soc open Sci*. 2017;4:170095. doi:10.1098/rsos.170095.
5. Shaw S, DeMarco SF, Rehmann R, Wenzler T, Florini F, Roditi I, et al. Flagellar cAMP signaling controls trypanosome progression through host tissues. *Nat Commun*. 2019;10.
6. Furger A, Schürch N, Kurath U, Roditi I. Elements in the 3' untranslated region of procyclin mRNA regulate expression in insect forms of *Trypanosoma brucei* by modulating RNA stability and translation. *Mol Cell Biol*. 1997;17:4372–80. doi:10.1128/mcb.17.8.4372.
7. Dean S, Sunter J, Wheeler RJ, Hodgkinson I, Gluenz E, Gull K. A toolkit enabling efficient, scalable and reproducible gene tagging in trypanosomatids. *Open Biol*. 2015;5:140197. doi:10.1098/rsob.140197.
8. Hutchings NR, Donelson JE, Hill KL. Trypanin is a cytoskeletal linker protein and is required for cell motility in African trypanosomes. *J Cell Biol*. 2002;156:867–77. doi:10.1083/jcb.200201036.
9. Lillico S, Field MC, Blundell P, Coombs GH, Mottram JC. Essential roles for GPI-anchored proteins in African trypanosomes revealed using mutants deficient in GPI8. *Mol Biol Cell*. 2003;14:1182–94. doi:10.1091/mbc.e02-03-0167.
10. Schumann Burkard G, Jutzi P, Roditi I. Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. *Mol Biochem Parasitol*. 2011;175:91–4. doi:https://doi.org/10.1016/j.molbiopara.2010.09.002.
11. Burkard G, Fragoso CM, Roditi I. Highly efficient stable transformation of bloodstream forms of *Trypanosoma brucei*. *Mol Biochem Parasitol*. 2007;153:220–3. doi:https://doi.org/10.1016/j.molbiopara.2007.02.008.
12. Brun R, Jenni L, Tanner M, Schönenberger M, Schell KF. Cultivation of vertebrate infective forms derived from metacyclic forms of pleomorphic *Trypanosoma brucei* stocks. Short communication. *Acta Trop*. 1979;36:387–90. <http://www.ncbi.nlm.nih.gov/pubmed/44103>.
13. Schädeli D, Serricchio M, Ben Hamidane H, Loffreda A, Hemphill A, Beneke T, et al. Cardiolipin depletion-induced changes in the *Trypanosoma brucei* proteome. *FASEB J*. 2019;33:13161–75.
14. Adli M. The CRISPR tool kit for genome editing and beyond. *Nat Commun*. 2018;9:1911. doi:10.1038/s41467-018-04252-2.
15. Pickar-Oliver A, Gersbach CA. The next generation of CRISPR–Cas technologies and applications. *Nat Rev Mol Cell Biol*. 2019;20:490–507. doi:10.1038/s41580-019-0131-5.

Figures




Figure 1

Plasmid maps of A) pTB011_Cas9_T7RNAP_blast and B) pAi1C9.




Figure 2

Trypanosomes tagged with mNeonGreen at the C-terminus of phosphodiesterase B1 (PDEB1). A) Tagging PDEB1 in Lister 427/Cas9. Scale bar: 10 microns. B) Tagging PDEB1 in Lister 427. Fluorescence intensity of live cells was quantified with a benchtop flow cytometer (ACEA NovoCyte). To remove particles of subcellular size, a cut-off of 3×10^4 was applied to the forward scatter. A total of 104 events were recorded and analysed using FlowJo software without gating. TF: transfection.




Figure 3

Flow chart of sequential transfections. Procyclic form trypanosomes were transfected first with pAi1C9 to allow expression of Cas9 and T7RNAP. After 20 hours, the pool of trypanosomes was transfected a second time to provide the templates for gRNA(s) and the repair template(s) / resistance cassette(s).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.pdf](#)